Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 04:44
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
RISE™Robotics Awarded $1.25 Million Contract to Modernize United States Air Force Ground Equipment
China-based hackers have breached government and individual email accounts, Microsoft says
Ford CEO Predicts 1,000% Growth for In-Car Software Services
SEC enforcement chief rejects criticism of crypto crackdown
TikTok: 3 easy steps to undo a repost on Gen's favorite platform
'Sophisticated' prosthetic hand found on medieval skeleton
Planview Redefines Strategic Decision-Making with Advanced AI
Asus ProArt B760-Creator D4 Review